Dorzolamide Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Dorzolamide Indications
Indications
Dorzolamide Dosage and Administration
Adults and Children
Renal Impairment
Dorzolamide has not been studied in patients with severe renal impairment (CrCl <30 mL/min). Because dorzolamide and its metabolite are excreted predominantly by the kidney, dorzolamide is not recommended in such patients.
Hepatic Impairment
Dorzolamide has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.
Dorzolamide Contraindications
Not Applicable
Dorzolamide Boxed Warnings
Not Applicable
Dorzolamide Warnings/Precautions
Warnings/Precautions
Discontinue if ocular effects (eg, conjunctivitis, lid reactions) occur. Low endothelial cell counts. Contact lenses: remove prior to administration; may reinsert 15mins after dose. Hepatic impairment. Severe renal impairment (CrCl <30mL/min): not recommended. Pregnancy. Nursing mothers.
Dorzolamide Pharmacokinetics
Distribution
Plasma concentrations of dorzolamide and metabolite are generally below the assay limit of quantitation (15nM). Dorzolamide binds moderately to plasma proteins (approximately 33%).
Elimination
Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine. After dosing is stopped, dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about 4 months.